PIII vs. XGN, DCGO, EUDA, SERA, QIPT, CORBF, NAKA, KDLY, ATPC, and BNR
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Exagen (XGN), DocGo (DCGO), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.
P3 Health Partners vs. Its Competitors
Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.
In the previous week, Exagen had 6 more articles in the media than P3 Health Partners. MarketBeat recorded 8 mentions for Exagen and 2 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.94 beat Exagen's score of 0.58 indicating that P3 Health Partners is being referred to more favorably in the news media.
75.3% of Exagen shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 17.8% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Exagen currently has a consensus price target of $9.00, indicating a potential upside of 23.80%. P3 Health Partners has a consensus price target of $16.25, indicating a potential upside of 123.52%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than Exagen.
P3 Health Partners has a net margin of -9.27% compared to Exagen's net margin of -27.34%. P3 Health Partners' return on equity of -123.10% beat Exagen's return on equity.
Exagen has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Summary
Exagen and P3 Health Partners tied by winning 8 of the 16 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 7/26/2025 by MarketBeat.com Staff
Free PIII Stock Alerts